Skip to main content

Table 1 Patient and tumor characteristics

From: CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Characteristic Number of patients (percentage)
Age  
   <50 years 19 (42)
   ≥50 years 26 (58)
HER-2 a  
   IHC (score 3+) 26 (58)
   FISH-positive 42 (95)
Estrogen receptor-positive  
   Yes 17 (38)
   No 28 (62)
Progesterone receptor-positive  
   Yes 10 (22)
   No 35 (78)
Nuclear grade  
   Intermediate 14 (31)
   High 31 (69)
Tumor size (baseline)  
   T1 5 (11)
   T2 24 (53)
   T3 8 (18)
   T4 8 (18)
Nodal status (baseline)  
   N0 19 (42)
   N1-N3 26 (58)
  1. aAll tumors were HER-2-positive by either IHC (score, 3+) and/or FISH. Not every patient had both tests. Two tumors were 2+ by IHC and positive by FISH, and one tumor was 3+ by IHC and negative by FISH. FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.